SCHEMBL679999

SCHEMBL679999

Oc1cc2cn(C3CCCCO3)nc2cc1Br

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.35
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP2C19 P33261 1/20 0.33
CYP4F2 P78329 2/20 0.32
CYP4A11 Q02928 2/20 0.32
CD274 Q9NZQ7 1/20 0.31
KDM5B Q9UGL1 1/20 0.31
PDE10A Q9Y233 1/20 0.31
RXRA P19793 1/20 0.30
RXRB P28702 1/20 0.30
RXRG P48443 1/20 0.30
RET P07949 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31600258 0.82 ABL1 (0.35) ABL1ALDH1A1POLBKMT2ASMN1; SMN2
SCHEMBL27401949 0.80 ABL1 (0.34) ABL1ALDH1A1POLBKMT2ASMN1; SMN2
SCHEMBL981891 0.79 ABL1 (0.38) ABL1ALDH1A1POLBKMT2ASMN1; SMN2
SCHEMBL23884655 0.77 IRAK4 (0.41) ABL1ALDH1A1SMN1; SMN2
SCHEMBL22836258 0.76 FLT3 (0.37) ABL1ALDH1A1POLBKMT2ASMN1; SMN2
SCHEMBL22836227 0.76 ATR (0.37) ABL1ALDH1A1POLBKMT2ASMN1; SMN2
SCHEMBL31600834 0.74 ABL1 (0.35) ABL1ALDH1A1POLBCYP2C19CYP4F2
SCHEMBL31550224 0.74 ALDH1A1 (0.33) ABL1ALDH1A1POLBKMT2ASMN1; SMN2
SCHEMBL22708144 0.74 ABL1 (0.41) ABL1ALDH1A1KMT2ASMN1; SMN2CYP2C19
SCHEMBL1141804 0.74 ABL1 (0.38) ABL1ALDH1A1POLBKMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC ABL1 16/4885ALDH1A1 1450/4885POLB 4665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.